An increasing body of subsequent research has challenged the usefulness of the healthcare-associated pneumonia label, including studies that have cast doubt on links between multidrug-resistant pathogens and increased mortality.
A multidisciplinary panel of experts put together by the American Thoracic Society and Infectious Diseases Society of America released updated recommendations for the management of adults with community-acquired pneumonia.
A shift toward personalized medicine in pneumonia management would involve refining the diagnostic categories to include viral pneumonia, bacterial pneumonia, and noninfectious respiratory disease.
ICD-9 organism-specific administrative codes for pneumonia appear to underestimate the prevalence of specific disease-associated pathogens in hospitalized patients.
The Food and Drug Administration has approved Recarbrio™ for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial.
The FDA has granted Priority Review to cefiderocol for the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible Gram-negative pathogens.
Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in combination with methotrexate (MTX) was shown to be successful and well-tolerated in patients with chronic inflammatory/autoimmune diseases.
